🔍

SMSPHARMA - SMS Pharma.

📊 NSE: SMSPHARMA 🏢 Pharmaceuticals - Indian - Bulk Drugs 📅 Last Updated: 12/14/2025 13:31

📢 Recent Corporate Announcements

SMS Pharma Q3FY26 PAT Grows 29% YoY to ₹23.5 Cr; EBITDA Margins Cross 20%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:23 PM

SMS Pharmaceuticals reported a strong Q3FY26 with revenue growing 21% YoY to ₹210.45 crore, driven by volume growth in key APIs. Net profit (PAT) increased by 29% YoY to ₹23.47 crore, while EBITDA margins improved to 20.74% due to backward integration benefits. The company achieved its annual target of 10 filings ahead of schedule and is on track with its ₹280 crore capex plan. Management maintained a positive outlook for FY26, targeting 20% revenue growth and sustained margins.

Revenue from operations grew 21% YoY to ₹210.45 crore in Q3FY26.
PAT for 9MFY26 surged 42% YoY to ₹69.27 crore, reflecting strong operational leverage.
EBITDA margins expanded by 158 bps YoY to 20.74%, supported by backward integration.
Significant 9MFY26 growth of 85% each in ARV, Anti-epileptic, and Anti-anginal therapeutic segments.
₹280 crore capacity expansion programme is on track for completion by FY27.

💡 Investors should monitor the company's progress on its ₹280 crore capex plan and its ability to maintain the 20% EBITDA margin guidance. The strong growth in niche therapeutic areas and early R&D filings suggest a robust future pipeline.

SMS Pharma Q3 FY26 Revenue up 21% YoY to ₹210 Cr; PAT grows 29% to ₹23.5 Cr

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 09 Feb 2026, 07:18 PM

SMS Pharmaceuticals reported a strong Q3 FY26 with revenue growing 21% YoY to ₹210.45 crore, driven by volume growth in key APIs. EBITDA margins improved to 21% from 19% YoY, aided by operating leverage and a better product mix. The company is on track to achieve its 20% revenue growth guidance for FY26 and is progressing with a ₹280 crore capex plan. Net profit for the nine-month period grew significantly by 42% YoY to ₹69.27 crore.

Revenue from operations increased 21% YoY to ₹210.45 crore in Q3 FY26
EBITDA grew 31% YoY to ₹44 crore with margins expanding 158 bps to 21%
PAT after associate profit rose 29% YoY to ₹23.47 crore
Company is executing a ₹280 crore capex program to be completed by FY27
High-value products now contribute 45% of the portfolio, supporting gross margin expansion

💡 Investors should monitor the progress of the ₹280 crore capex and the company's ability to maintain 20%+ margins. The stock remains attractive given the 42% 9M PAT growth and leadership in key API segments.

SMS Pharma Reports Zero Deviation in Utilization of Rs 114.30 Cr Raised via Warrants

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 07 Feb 2026, 04:52 PM

SMS Pharmaceuticals has confirmed no deviation in the utilization of Rs 114.30 crores raised through a preferential issue of 90 lakh warrants. As of December 31, 2025, the company has utilized Rs 80.93 crores, primarily focusing on capital expenditure for production expansion and backward integration. A sum of Rs 33.35 crores has been temporarily deployed toward working capital to reduce finance costs, which the Audit Committee has advised be re-transferred for project execution as needed. The company is progressing with its plan to set up new production blocks for Key Starting Materials (KSM).

Total issue size of Rs 114.30 crores fully raised following conversion of 90,00,000 warrants.
Cumulative utilization of funds stands at Rs 80.93 crores as of December 31, 2025.
Rs 48.05 crores utilized for CapEx and expansion of production capacities against an allocation of Rs 62.87 crores.
Temporary deployment of Rs 33.35 crores in working capital to optimize finance costs pending project execution.
Funds are being directed toward backward integration of Key Starting Materials (KSM) for existing and pipeline products.

💡 Investors should track the completion of the production capacity expansion and KSM backward integration, as these are key to long-term margin improvement. The temporary use of funds for working capital is a standard treasury management practice and does not indicate a change in the company's strategic objectives.

SMSPHARMA Q3 Net Profit Rises 29% YoY to ₹23.47 Cr; Board OKs ₹7 Cr Subsidiary Investment

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 07 Feb 2026, 04:40 PM

SMS Pharmaceuticals reported a strong year-on-year performance for Q3 FY26, with consolidated revenue growing 21.4% to ₹210.45 crore compared to ₹173.35 crore in the same quarter last year. Net profit for the quarter stood at ₹23.47 crore, a significant 28.7% increase from ₹18.24 crore YoY, although it saw a slight sequential dip from ₹25.31 crore in Q2. For the nine-month period, the company demonstrated robust growth with profits surging 42% to ₹69.28 crore. Additionally, the board approved a strategic investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited, to strengthen its presence in the peptide segment.

Consolidated Revenue from Operations grew 21.4% YoY to ₹210.45 crore in Q3 FY26.
Net Profit after tax increased by 28.7% YoY to ₹23.47 crore.
Nine-month (9M FY26) Net Profit reached ₹69.28 crore, a 41.9% increase over 9M FY25.
Board approved a further investment of up to ₹7 crore in subsidiary SMS Peptides Private Limited.
Basic EPS for the quarter improved to ₹2.59 from ₹2.15 in the previous year's corresponding quarter.

💡 Investors should take note of the strong year-on-year growth and the strategic focus on the peptide segment. While there was a minor sequential decline, the overall nine-month trajectory remains robust, suggesting healthy operational momentum.

SMSPHARMA Q3 Net Profit Rises 29% YoY to ₹23.47 Cr; To Invest ₹7 Cr in Peptide Subsidiary

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 07 Feb 2026, 04:34 PM

SMS Pharmaceuticals reported a strong year-on-year performance for the quarter ended December 31, 2025, with consolidated revenue growing 21.4% to ₹210.45 crore. Net profit for the quarter increased by 28.7% YoY to ₹23.47 crore, although it saw a sequential decline of 7.3% from the previous quarter. The company's nine-month performance remains robust, with net profit jumping nearly 42% compared to the same period last year. Additionally, the board approved a strategic investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited, to expand its specialized portfolio.

Consolidated Revenue from operations grew 21.4% YoY to ₹210.45 crore from ₹173.35 crore.
Net Profit after tax increased 28.7% YoY to ₹23.47 crore compared to ₹18.24 crore in Q3 FY25.
Nine-month (9M FY26) Net Profit reached ₹69.28 crore, a 41.9% increase over ₹48.82 crore in 9M FY25.
Board approved a fresh investment of up to ₹7 crore in subsidiary SMS Peptides Private Limited via equity.
Earnings Per Share (EPS) improved to ₹2.59 for the quarter, up from ₹2.15 in the year-ago period.

💡 Investors should take note of the strong year-on-year growth and the company's move to further capitalize on its peptide subsidiary. While the sequential dip in revenue warrants monitoring, the overall nine-month growth trajectory remains healthy.

SMS Pharmaceuticals Reports Nil Physical Share Transfer Requests for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 17 Jan 2026, 03:25 PM

SMS Pharmaceuticals Limited has submitted its status report regarding the special window for re-lodgement of physical share transfer requests as mandated by SEBI. For the reporting period from December 1, 2025, to January 6, 2026, the company reported zero requests received from shareholders. Consequently, no transfers were processed, approved, or rejected during this timeframe. This filing is a standard regulatory compliance procedure and has no material impact on the company's operations or financial health.

Zero (NIL) requests received for re-lodgement of physical share transfers during the period.
Report covers the specific window from December 1, 2025, to January 6, 2026.
No requests were processed, approved, or rejected by the Registrar and Share Transfer Agent.
Compliance follows SEBI Circular No. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 2, 2025.

💡 No action is required from investors as this is a routine regulatory filing with no impact on business fundamentals.

SMS Pharmaceuticals Files Quarterly SEBI Compliance Certificate for Dec 2025

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 07 Jan 2026, 05:52 PM

SMS Pharmaceuticals Limited has submitted its compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, provided by Aarthi Consultants Private Limited, confirms that all security certificates received for dematerialization were processed within the mandatory 15-day window. This filing ensures that physical certificates were properly mutilated, cancelled, and the depository's name was updated in the records. This is a standard administrative procedure required for all listed entities in India.

Compliance certificate submitted for the quarter ended December 31, 2025.
RTA confirmed processing of dematerialization requests within 15 days of receipt.
Physical security certificates were mutilated and cancelled as per SEBI regulations.
Depository names were substituted as registered owners in the company records.

💡 No action is required from investors as this is a routine regulatory filing confirming the company's administrative compliance.

SMS Pharmaceuticals to Close Trading Window from January 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Dec 2025, 03:01 PM

SMS Pharmaceuticals Limited has announced the closure of its trading window for all designated persons and their immediate relatives starting January 1, 2026. This action is taken in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of financial results for the third quarter and nine months ending December 31, 2025. The trading window will remain closed until 48 hours after the financial results are made public. The specific date for the Board Meeting to consider these results will be communicated at a later date.

Trading window closure begins on January 1, 2026, for all designated persons.
Closure is related to the upcoming Q3 and nine-month financial results ending December 31, 2025.
The window will reopen 48 hours after the official declaration of financial results.
Compliance is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

💡 This is a routine regulatory announcement with no immediate impact on stock fundamentals; investors should wait for the upcoming earnings release to assess company performance.

SMS Pharma Invests ₹3.99 Crore in Subsidiary SMS Peptides for R&D Expansion

🟡 NEUTRAL ⭐ 4/10

EXPANSION 📅 26 Dec 2025, 06:40 PM

SMS Pharmaceuticals has increased its stake in its subsidiary, SMS Peptides Private Limited, from 99.98% to 99.99% through a rights issue subscription. The company invested ₹3.99 crore by acquiring 39,90,000 equity shares at a par value of ₹10 each. These funds are specifically designated for the procurement of machinery and equipment to facilitate R&D activities within the subsidiary. SMS Peptides, incorporated in November 2024, is currently in its implementation stage and has yet to commence revenue-generating operations.

Invested ₹3.99 crore to acquire 39,90,000 equity shares at ₹10 each
Increased shareholding in SMS Peptides Private Limited to 99.99%
Capital earmarked for R&D machinery and equipment procurement
Subsidiary is in implementation stage with zero revenue since Nov 2024 incorporation

💡 Investors should view this as a routine capital infusion for a nascent business vertical. Monitor future updates regarding the subsidiary's transition from R&D to commercial operations to gauge long-term value.

SMS Pharma Incorporates Wholly Owned Subsidiary SMS coLab for Greenfield Expansion

🟢 POSITIVE ⭐ 6/10

EXPANSION 📅 24 Dec 2025, 11:51 AM

SMS Pharmaceuticals has successfully incorporated a new wholly owned subsidiary, SMS coLab Private Limited, as of December 23, 2025. This new entity is established as a greenfield project to focus on the research, development, and manufacturing of pharmaceutical products in new therapeutic categories. The company invested an initial cash consideration of Rs. 1,00,000 for a 100% equity stake, with an authorized capital of Rs. 15,00,000. This strategic move aims to expand the company's footprint in the formulations sector and enhance its global market reach.

Incorporation of 'SMS coLab Private Limited' as a 100% subsidiary on December 23, 2025.
Initial paid-up capital of Rs. 1,00,000 with an authorized capital of Rs. 15,00,000.
Subsidiary to focus on greenfield projects in new therapeutic categories and R&D.
Business scope includes manufacturing, marketing, and global distribution of APIs and formulations.
The move is intended to establish strategic partnerships and joint ventures globally.

💡 Investors should view this as a long-term growth signal and monitor future CAPEX announcements related to this greenfield project. No immediate impact on earnings is expected as the subsidiary is yet to commence operations.

SMS Pharma: USFDA inspects Vizag facility, issues one minor observation

🟡 NEUTRAL ⭐ 6/10

REGULATORY 📅 12 Dec 2025, 07:58 PM

SMS Pharmaceuticals Limited announced the successful completion of a USFDA inspection at its API manufacturing facility in Visakhapatnam from December 8 to December 12, 2025. The inspection concluded with one minor procedural observation in Form 483, which does not relate to data integrity. The Vizag facility is a 3,000 KL flagship API manufacturing facility with multiple global regulatory approvals. This marks the 4th inspection for this facility and the 12th across SMS Pharma's manufacturing sites.

USFDA inspection completed at Vizag facility from December 8 to December 12, 2025
One minor observation in Form 483 issued by USFDA
Vizag facility is a 3,000 KL API manufacturing facility
Facility has 12 regulatory approvals including USFDA, WHO-GMP and EU-GMP
This is the 4th USFDA inspection for the Vizag facility

💡 Investors should monitor the company's response to the USFDA observation and any subsequent updates. The successful inspection supports continued API supply to international markets.

View All SMSPHARMA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

The Anti-Retroviral (ARV) segment saw a significant recovery, increasing its revenue contribution to 20% in FY24 from just 3% in FY23. Ibuprofen revenue grew 1.6x in FY24. Overall revenue for Q2 FY26 reached INR 242 Cr, a 23% YoY increase from INR 197 Cr in Q2 FY25. FY25 total revenue stood at INR 788 Cr, up 11% from INR 712 Cr in FY24.

Geographic Revenue Split

As of Q2 FY26, the revenue split is: EOU/SEZ/DE Sales (27%), Europe (26%), North America (24%), India (15%), and Asia excluding India (9%). Regulatory markets collectively account for 88% of total revenue.

Profitability Margins

Net Profit Margin improved to 8.74% in FY25 from 6.97% in FY24, a 25% increase. Gross margins expanded by 30% YoY in Q2 FY26, primarily driven by successful backward integration initiatives. Return on Net Worth increased by 19% to reach 11.00% in FY25.

EBITDA Margin

EBITDA margin stood at 20% in Q2 FY26, representing a 54% YoY increase. The operating profit margin for FY25 was 18.68%, up 9% from 17.10% in FY24. The company targets a sustained 20% EBITDA margin for FY26 through operating leverage and backward integration.

Capital Expenditure

The company is executing a INR 280 Cr capex program scheduled for completion by November 2026. This follows a previous INR 250 Cr capex aimed at driving new product launches and expanding the CMO business.

Credit Rating & Borrowing

Long-term bank facilities (INR 350.87 Cr) are rated CARE A; Positive (upgraded from Stable). Short-term facilities (INR 52.83 Cr) were upgraded to CARE A1 from CARE A2+. Interest coverage ratio improved 47% to 7.89x in FY25 due to higher EBITDA.

⚙️ Operational Drivers

Raw Materials

Key raw materials include intermediates for Ibuprofen and ARV drugs. While specific chemical names are not listed, backward integration for these materials is a core strategy to reduce the 30% margin volatility previously experienced.

Import Sources

The company is actively reducing dependence on imports through backward integration, particularly to mitigate risks from international supply chains in Asia and Europe.

Capacity Expansion

Current total reactor volume is 3,120 KL. The company operates one of Asia’s largest production blocks for Ibuprofen at its Vishakhapatnam facility. Planned expansion via the INR 280 Cr capex aims to support 8-10 new product launches in the next 12-18 months.

Raw Material Costs

Raw material costs are being optimized through backward integration, which contributed to a 30% YoY expansion in gross margins in Q2 FY26. Historically, input price escalation in FY23 led to negative margins in the Ibuprofen segment before stabilizing.

Manufacturing Efficiency

The company targets a net asset turnover of 1.5x, which it identifies as among the best in the industry. Efficiency is driven by advanced plant engineering and a large technical team of 100+ scientists.

Logistics & Distribution

Export sales, including deemed exports, constituted approximately 67% of gross sales revenue in FY23, requiring extensive global distribution networks to serve 800+ customers.

📈 Strategic Growth

Expected Growth Rate

20%

Growth Strategy

Growth will be achieved through a three-pronged strategy: completing the INR 280 Cr backward integration project to boost margins, launching 8-10 new products in therapeutic areas like anti-diabetic and anti-migraine, and expanding the CMO business. The company also leverages its JV with Spanish giant Chemo Iberica S.A. to penetrate regulated markets.

Products & Services

Active Pharmaceutical Ingredients (APIs) and intermediates for therapeutic segments including Anti-Retroviral (ARV), Anti-Diabetic, Anti-Inflammatory (Ibuprofen), Anti-Migraine (Triptans), and Anti-Ulcerants.

Brand Portfolio

SMS Pharmaceuticals Limited (Corporate Brand).

New Products/Services

Planned launch of 8-10 new products in the next 12-18 months. Since FY22, 20 new products have already been added to the portfolio.

Market Expansion

Focusing on strengthening presence in regulated markets (US and Europe) which currently contribute to the majority of export revenue. The company currently exports to over 75 countries.

Market Share & Ranking

The company claims #1 global and domestic leadership in key products, including being the world's largest manufacturer of Ranitidine API historically and a leader in anti-migraine triptans.

Strategic Alliances

Maintains a strategic Joint Venture (JV) with Spanish pharmaceutical company Chemo Iberica S.A. for product development and market access.

🌍 External Factors

Industry Trends

The Indian API industry is shifting toward backward integration to reduce China-dependency and moving toward niche, high-value molecules. SMS is positioned as a vertically integrated player with a focus on R&D and globally compliant facilities.

Competitive Landscape

Operates in a highly competitive and fragmented API market. Key competitors include large and mid-sized Indian and global API manufacturers in the ARV and Ibuprofen segments.

Competitive Moat

Moat is built on high switching costs for regulated market customers, 120+ DMF filings, and USFDA/PMDA approved facilities (Unit II and VII). These are sustainable due to the complex, lengthy, and expensive nature of the regulatory approval process for new competitors.

Macro Economic Sensitivity

Sensitive to global pharmaceutical demand and Indian government 'pro-policies' for API exports, which are projected to grow at an 8.3% CAGR to $22 billion by 2030.

Consumer Behavior

Increasing global prevalence of chronic diseases like diabetes and migraine is fueling long-term demand for the company's specific API portfolio.

Geopolitical Risks

Trade barriers and regulatory changes in the US and Europe (regulated markets) pose risks to the 88% of revenue sourced from these regions.

⚖️ Regulatory & Governance

Industry Regulations

Strict adherence to USFDA, PMDA Japan, EDQM (Europe), and ANVISA (Brazil) standards is mandatory for operations. Non-compliance risks include regulatory bans on products or facilities.

Environmental Compliance

The company provides comprehensive safety training and manages environment hazards; it complies with corporate governance as per SEBI (LODR) regulations.

⚠️ Risk Analysis

Key Uncertainties

Regulatory risk is the primary uncertainty; any adverse finding by the USFDA could impact 88% of revenue. Raw material price volatility and the successful timely completion of the INR 280 Cr capex are also critical.